What is maintenance therapy for Neuroendocrine Tumors and when is it recommended

Maintenance Therapy for Neuroendocrine Tumors

What Is Maintenance Therapy?

Maintenance therapy refers to ongoing treatment given after initial treatment to help keep the cancer controlled and prevent it from coming back or progressing. Think of it as a "holding strategy" — rather than aggressive chemotherapy, maintenance uses gentler, longer-term approaches to manage the disease.

For neuroendocrine tumors (NETs), maintenance therapy is quite different from many other cancers because there is currently no established role for adjuvant (post-surgery) chemotherapy according to NCCN Guidelines. This is an important distinction.

---

When Is Maintenance Therapy Recommended?

For Patients with Stable, Low-Burden Disease

According to NCCN Guidelines for Neuroendocrine Tumors, maintenance approaches are typically considered when you have:

• Asymptomatic disease (no symptoms)
• Low tumor burden (limited amount of cancer)
• Stable disease (cancer isn't growing or shrinking significantly)

In these situations, your doctors may recommend:

1. Somatostatin Analogs (SSAs) - First-Line Maintenance

The most common maintenance options are:

• Octreotide LAR (long-acting release) - given as an injection every 4 weeks
• Lanreotide - also given as an injection every 4 weeks

How they work: These medications mimic a natural hormone called somatostatin, which can slow tumor growth and help control hormone-related symptoms (like flushing or diarrhea).

When they're used:

• If your tumor is SSTR-positive (meaning it has somatostatin receptors that these drugs can target)
• If you have hormonal symptoms that need control
• The PROMID and CLARINET clinical trials showed these drugs can slow tumor progression in advanced, well-differentiated NETs

2. Observation with Monitoring

For some patients with very stable, indolent (slow-growing) disease, your doctors may recommend:

• Active surveillance rather than medication
• Regular imaging (CT or MRI scans) every 3-6 months
• Blood tests to monitor tumor markers
• This approach avoids medication side effects while watching for any changes

---

Maintenance Therapy by Tumor Type

Gastrointestinal (GI) NETs

According to NCCN Guidelines, for patients with well-differentiated Grade 1/2 GI NETs with metastatic disease:

• Octreotide LAR or lanreotide are preferred for SSTR-positive tumors
• Standard doses: octreotide LAR 20-30 mg IM or lanreotide 120 mg SC every 4 weeks
• If you progress on standard doses, higher doses (up to 60 mg octreotide LAR monthly or lanreotide every 14 days) may be considered

Pancreatic NETs (PanNETs)

For asymptomatic patients with low tumor burden and stable disease:

• Octreotide LAR or lanreotide can be considered if SSTR-positive
• Observation alone is also an acceptable option
• If you have functional tumors (producing hormones), maintenance therapy helps control symptoms

Lung/Thymic NETs

For patients with low-grade (typical carcinoid) disease and low tumor burden:

• Octreotide LAR or lanreotide if SSTR-positive and/or symptomatic
• The SPINET trial showed lanreotide provided a median progression-free survival of 16.6 months in bronchopulmonary NETs

---

Important Clinical Considerations

When Maintenance Therapy Is NOT Recommended

• After surgery for localized disease - there is no proven benefit to chemotherapy after complete resection
• For high-grade or poorly differentiated NETs - these typically require more aggressive systemic therapy rather than maintenance
• If your disease is progressing - you would typically move to active treatment rather than maintenance

What Happens If Your Disease Progresses?

If you develop:

• Clinical progression (symptoms worsening)
• Radiographic progression (tumors growing on imaging)
• Biochemical progression (tumor markers rising)

Your doctor will typically discontinue maintenance SSAs (for non-functional tumors) and move to more active systemic therapy options like:

• Everolimus (mTOR inhibitor)
• Lutetium Lu 177 dotatate (PRRT - peptide receptor radionuclide therapy) if SSTR-positive
• Cabozantinib (tyrosine kinase inhibitor)
• Chemotherapy in select cases

---

Questions to Ask Your Oncology Team

1. Is my tumor SSTR-positive? This determines whether SSAs will be effective for me.

2. What is my current tumor burden and disease status? Am I a candidate for maintenance therapy or observation?

3. If you recommend octreotide or lanreotide, what dose and schedule do you suggest, and how will we monitor for effectiveness?

4. How often will we do imaging and blood tests to monitor my disease? (Typically every 3-6 months for stable disease)

5. What are the side effects of maintenance therapy, and how will we manage them?

6. What signs should prompt me to contact you immediately? (Worsening symptoms, new symptoms, etc.)

7. If my disease progresses on maintenance therapy, what are my next treatment options?

---

Key Takeaway

Maintenance therapy for NETs is fundamentally different from many other cancers — it's often about long-term disease control rather than aggressive treatment. For patients with stable, low-burden disease, somatostatin analogs or careful observation can effectively manage the disease while maintaining quality of life. The goal is to keep your cancer stable while minimizing side effects.

According to NCCN Guidelines, the decision to use maintenance therapy should be individualized based on your specific tumor characteristics, disease burden, and symptoms.

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.